Go beyond the numbers to analytics-driven insights using artificial intelligence, machine learning and healthcare expertise.
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREYour new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSMergers and acquisitions (M&A) in the biopharmaceutical sector experienced a notable resurgence in the fourth quarter of 2023, with an increase in both the overall deal value and volume of these transactions. Despite facing challenges such as macroeconomic factors and regulatory obstacles, biopharmaceutical companies actively pursued substantial M&A endeavors towards the end of 2023 with around 70% of these transactions carried out by big pharma companies and driven by novel, innovative therapies and technologies.
In the fourth quarter of 2023, the life science industry experienced a surge in M&A deals including several significant announcements from big pharma, reflecting the dynamic changes in the dealmaking landscape after a slow start in 2023. The primary objectives behind these transactions were to introduce innovative therapeutics to portfolios to tackle emerging medical challenges as well as address imminent expiration of patents for key products.
The total number of biopharma M&A deals in Q4 2023 was up compared to previous quarters. According to the Pharma Deals database, there were 19% more transactions during this period as compared to Q3 2023. The aggregate total deal value for biopharma M&A deals signed in Q4 2023 reached an impressive $69.08 billion, up by 157% compared to the previous quarter. The average value of biopharma M&A deals in Q4 2023 was $706.2 million, a substantial increase from the previous quarters, underscoring the strategic importance attached to these transactions. Deals were focused on a diverse range of therapeutic areas and primarily targeted de-risked entities, emphasizing assets in Phase III or those already on the market. Oncology and immunology remained prominent as the key therapeutic areas. Notably, there was a significant presence of acquisitions focused on neuroscience, indicating a resurgence of interest in central nervous system (CNS) innovation.
To read more, fill in your details on the left to download the article.
Go beyond the numbers to analytics-driven insights using artificial intelligence, machine learning and healthcare expertise.